Eli Lilly (LLY)
775.10
-0.35 (-0.05%)
NYSE · Last Trade: Jun 30th, 8:36 PM EDT
Detailed Quote
Previous Close | 775.45 |
---|---|
Open | 778.54 |
Bid | 774.55 |
Ask | 775.39 |
Day's Range | 774.64 - 785.00 |
52 Week Range | 677.09 - 972.53 |
Volume | 195,662 |
Market Cap | 741.44B |
PE Ratio (TTM) | 63.07 |
EPS (TTM) | 12.3 |
Dividend & Yield | 6.000 (0.77%) |
1 Month Average Volume | 3,076,393 |
Chart
About Eli Lilly (LLY)
Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
News & Press Releases
The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide.
Via Investor's Business Daily · June 30, 2025
Timing matters with biotech stocks; these three companies offer distinct risk-reward profiles but have upcoming catalysts that could redefine their value
Via MarketBeat · June 29, 2025
Artificial intelligence (AI) has the potential to transform several different areas of the healthcare industry.
Via The Motley Fool · June 29, 2025
Via The Motley Fool · June 28, 2025
BALA CYNWYD, Pa., June 27, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
By Brodsky & Smith LLC · Via GlobeNewswire · June 27, 2025
MHRA launches genetic study into GLP-1 drug risks as Spain investigates Novo Nordisk for potential advertising violations.
Via Benzinga · June 27, 2025
Local drugmakers, including Sun Pharma, Biocon, Zydus, Cipla, and Dr. Reddy’s are racing to develop cheaper versions of semaglutide as its Indian patent nears expiry.
Via Stocktwits · June 26, 2025
Via Stocktwits · June 26, 2025
Eli Lilly’s first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging competitive pressures. Management credited the surge in sales to the continued success of its diabetes and obesity medicines, particularly Mounjaro and Zepbound, which now account for a significant portion of total revenue. However, executives also acknowledged that higher marketing and R&D spending, as well as elevated costs tied to launching new products and acquiring late-stage assets, weighed on profitability. CEO Dave Ricks noted that the company is facing “a lot of investor focus right now on tariffs and trade,” while CFO Lucas Montarce cited a “26% increase in marketing, selling and administrative expenses” as Lilly ramped up promotion for new launches.
Via StockStory · June 26, 2025
GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only 8.1% stayed on therapy for three years.
Via Benzinga · June 25, 2025
The company just initiated two Phase 3 studies of its weekly under-the-skin shot to stoke weight loss.
Via Investor's Business Daily · June 25, 2025
Viking Therapeutics begins Phase 3 trials for VK2735, testing weekly injections in over 5,000 adults with obesity or type 2 diabetes over 78 weeks.
Via Benzinga · June 25, 2025
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.
Via Chartmill · June 25, 2025
Via The Motley Fool · June 25, 2025
Bimagrumab showed promising fat loss results in a mid-stage trial, but analysts raised concerns about safety and say more data is needed.
Via Stocktwits · June 25, 2025
Novo Nordisk launches Wegovy in India, pricing it close to Eli Lilly's Mounjaro, while advancing global regulatory efforts for its GLP-1 portfolio.
Via Benzinga · June 24, 2025
HIMS CEO said that the pharma company’s commercial team has been increasingly pressuring the company to control clinical standards and steer patients to Wegovy regardless of whether it is clinically best for patients.
Via Stocktwits · June 23, 2025